Department of Pharmacology, Kobe Pharmaceutical University, Kobe, Japan.
Immunology. 2014 Apr;141(4):617-27. doi: 10.1111/imm.12225.
Fab fragments (Fabs) maintain the ability to bind to specific antigens but lack effector functions due to the absence of the Fc portion. In the present study, we tested whether Fabs of an allergen-specific monoclonal antibody (mAb) were able to regulate asthmatic responses in mice. Asthmatic responses were induced in BALB/c mice by passive sensitization with anti-ovalbumin (OVA) polyclonal antibodies (pAbs) (day 0) and by active sensitization with OVA (days 0 and 14), followed by intratracheal (i.t.) challenge with OVA on day 1 and days 28, 29, 30 and 35. Fabs prepared by the digestion of an anti-OVA IgG1 (O1-10) mAb with papain were i.t. administered only once 30 min before antigenic challenge on day 1 or day 35. The results showed that i.t. administration of O1-10 Fabs with OVA markedly suppressed the early and/or late phases of asthmatic responses caused by passive and active sensitization. Similar results were obtained when Fabs of anti-OVA IgG2b mAb (O2B-3) were i.t. administered. In contrast, neither i.t. injection of intact 01-10/O2B-3 nor systemic injection of O1-10 Fabs suppressed the asthmatic responses. In vitro studies revealed that the capture of OVA by O1-10 Fabs prevented the subsequent binding of intact anti-OVA pAbs to the captured OVA. These results suggest that asthmatic responses may be down-regulated by the i.t. exposure to Fabs of an allergen-specific mAb via a mechanism involving the capture of allergen by Fabs in the respiratory tract before the interaction of intact antibody and allergen essential for the induction of asthmatic responses.
Fab 片段(Fabs)保留了与特定抗原结合的能力,但由于缺乏 Fc 部分,因此失去了效应功能。在本研究中,我们测试了过敏原特异性单克隆抗体(mAb)的 Fabs 是否能够调节小鼠的哮喘反应。通过用抗卵清蛋白(OVA)多克隆抗体(pAb)(第 0 天)被动致敏和用 OVA 主动致敏(第 0 天和第 14 天)诱导 BALB/c 小鼠的哮喘反应,然后在第 1 天和第 28、29、30 和 35 天用 OVA 经气管内(i.t.)挑战。用木瓜蛋白酶消化抗 OVA IgG1(O1-10)mAb 制备的 Fabs 仅在第 1 天或第 35 天抗原挑战前 30 分钟经 i.t. 给药一次。结果表明,在第 1 天或第 35 天经 i.t. 给予 OVA 的 O1-10 Fabs 可显著抑制由被动和主动致敏引起的哮喘反应的早相和/或晚相。当经 i.t. 给予抗 OVA IgG2b mAb(O2B-3)的 Fabs 时,也得到了类似的结果。相比之下,无论是经 i.t. 注射完整的 O1-10/O2B-3 还是系统注射 O1-10 Fabs 均未抑制哮喘反应。体外研究表明,O1-10 Fabs 捕获 OVA 可防止随后完整的抗 OVA pAb 与捕获的 OVA 结合。这些结果表明,哮喘反应可能通过一种机制被下调,该机制涉及在诱导哮喘反应所必需的完整抗体和过敏原相互作用之前,过敏原特异性 mAb 的 Fabs 在呼吸道中捕获过敏原。